Endocrinology, diabetes & metabolism · 2026
Impact of Short-Term Insulin Pump Therapy on Cardiometabolic Index in Patients With Newly Diagnosed Type 2 Diabetes Mellitus.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Xia, Li Shuya, Chen Zeren, Wang Dong, Yang Ling, Deng Xia, Li Haoxiang
Аннотация
OBJECTIVE: This study aims to investigate the changes in cardiometabolic index (CMI) levels in newly diagnosed type 2 diabetes mellitus (T2DM) patients before and after undergoing short-term continuous subcutaneous insulin infusion (CSII) intensive treatment and analyse its correlation with insulin resistance.
METHODS: This study retrospectively collected data from 604 patients who were initially diagnosed with T2DM and received short-term CSII treatment during their hospitalisation in the Endocrinology Department of the Affiliated Hospital of Jiangsu University. Clinical data, blood glucose, insulin, C-peptide, blood biochemistry, and other indicators were collected before and after treatment, and CMI was calculated.
RESULTS: Short-term CSII treatment significantly improved blood glucose levels, insulin resistance, and pancreatic β-cell function in T2DM patients, while downregulating the CMI index (p = 0.002). Correlation analysis showed a positive correlation between CMI and HOMA-IR (p < 0.001) and a negative correlation between CMI and HOMA-β (p = 0.008). Stepwise linear regression model analysis revealed that CMI was independently associated with fasting C-peptide (FCP) before treatment (β = 0.291, p < 0.001); after treatment, CMI was associated with FCP (β = 0.160, p < 0.001) and HOMA-IR (β = 0.159, p < 0.001).
CONCLUSION: After short-term intensive CSII treatment, the CMI level in newly diagnosed T2DM patients significantly decreased, indicating that intensive CSII treatment may have certain significance in improving cardiometabolic function.
METHODS: This study retrospectively collected data from 604 patients who were initially diagnosed with T2DM and received short-term CSII treatment during their hospitalisation in the Endocrinology Department of the Affiliated Hospital of Jiangsu University. Clinical data, blood glucose, insulin, C-peptide, blood biochemistry, and other indicators were collected before and after treatment, and CMI was calculated.
RESULTS: Short-term CSII treatment significantly improved blood glucose levels, insulin resistance, and pancreatic β-cell function in T2DM patients, while downregulating the CMI index (p = 0.002). Correlation analysis showed a positive correlation between CMI and HOMA-IR (p < 0.001) and a negative correlation between CMI and HOMA-β (p = 0.008). Stepwise linear regression model analysis revealed that CMI was independently associated with fasting C-peptide (FCP) before treatment (β = 0.291, p < 0.001); after treatment, CMI was associated with FCP (β = 0.160, p < 0.001) and HOMA-IR (β = 0.159, p < 0.001).
CONCLUSION: After short-term intensive CSII treatment, the CMI level in newly diagnosed T2DM patients significantly decreased, indicating that intensive CSII treatment may have certain significance in improving cardiometabolic function.